

NLG919

Catalog #: 27337-2

Lot #: 150203

Size: 50 mg


Structure:

CAS Registry #: 1402836-58-1

Purity: ≥98%

Chemical Formula: C₁₈H₂₂N₂O

Molecular Weight: 282.4



Description: NLG919 is an orally available potent inhibitor of the indoleamine-(2,3)-dioxygenase (IDO) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolism of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of $K_i = 7$ nM and $EC_{50} = 75$ nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer.

Synonym: 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol

Appearance: White powder

Solubility: Soluble in DMSO at 15 mg/ml.

Biological Activity: NLG919 potently blocks IDO-induced T cell suppression and restored T cell responses with a reported ED₅₀ of 80 nM *in vitro*. NLG919 reduced the concentration of plasma and tissue kynurenine by ~50% after a single dose in mice. NLG919 enhanced the antitumor responses of naïve, resting pmel-1 T-cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA in mice bearing B16F10 tumors.

Storage/Stability: Store as supplied at or below -20°C for up to 3 years. Stable in DMSO at -80°C for up to 6 months.

References:

1. Driessens, G., *et al.*, *J. Immunother. Cancer.* 2014; **2(Suppl 3)**:195.
2. Nayak, A., *et al.* *J. Immunother. Cancer.* 2014; **2(Suppl 3)**: 250.